Introduction
Carbapenems are well-known β-lactam antibiotics with broad spectrum activity that have long been used for treating severe infections caused by otherwise resistant Gram-negative bacteria (GNB). 1 Nevertheless, these agents have been misused to the extent that they are no longer effective due to the high rate of development of different resistant mechanisms that target them. 2 Among these resistant mechanisms, acquired carbapenem hydrolyzing enzymes (carbapenemases) emergence and their wide dissemination represented a global health threat which poses serious therapeutic and infection control challenges being associated with elevated mortality rates and increase in hospital stay. 3, 4 For these reasons, clinicians became highly concerned about rapidly identifying bacteria carrying these genes to reduce or prevent this problem in health care centers.
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Carbapenemases are diverse and include members of β-lactamase molecular classes A, B and D. 6 Class D oxacillinases (OXA type) are the most prevalent in Acinetobacter baumannii while in Pseudomonas aeruginosa, carbapenemases are mostly class B (metallo-β-lactamases). 7, 8 Although the definitions for MDR and XDR (multi-and extensively drug-resistant) GNB do not necessarily require resistance to carbapenems, 9 the carbapenem-resistant (CR) phenotype is very common for MDR and particularly for XDR isolates because carbapenemase-encoding genes are carried on mobile genetic elements that usually carry genetic determinants for resistance to other antibiotics. 10 The lack of effective antibiotics against CR-GNB and the drying out of the pipeline of new antibiotics forced physicians to recall old antibiotics (ie, polymyxins) back into clinical use. 11 Most CR-GNB, including those with XDR profile, show in vitro susceptibility to colistin. 12 However, the possibility of emergence of hetero-resistance and the low clinical efficacy of colistin in monotherapy in addition to its high toxicity, led to the utilization of colistin in combination with other antibiotics for desperately ill patients with serious infections especially in intensive care units (ICUs). 13 The E-test method for antibiotic combination testing is an easily performed, rapid method that showed good concordance with other methods used for evaluating the effect of antibiotic combinations. 14, 15 It is thus reliable when results are to be used in guiding combination therapies. 16 This study was conducted to characterize different carbapenemase genes carried by CR A. baumannii and P. aeruginosa isolates and to evaluate the in vitro effect of some colistin-based combinations by E-test method in Zagazig University Hospitals ICU isolates.
Materials and methods
Bacterial isolates and primary susceptibility testing
Fifty A. baumannii and 43 P. aeruginosa non-duplicate clinical isolates collected over a 6-month period (July 2017-December 2017) from the surgical ICU of Zagazig University Hospitals were included in the study. Identification was done by Vitek 2 system (Biomerieux, Marcy l'Etoile, France). The designation "A. baumannii" here is used to refer to the pathogenic members of the Acinetobacter baumannii complex.
Isolates were tested for antimicrobial susceptibility by the modified Kirby-Bauer disc diffusion method. Antimicrobial susceptibility included that of carbapenems (imipenem and meropenem), aminoglycosides (amikacin and tobramycin), antipseudomonal penicillin/β-lactamase inhibitor ( piperacillin/ tazobactam), monobactam (aztreonam), broad spectrum cephalosporins (ceftazidime, cefepime), and antipseudomonal fluoroquinolones (ciprofloxacin, levofloxacin). Minimum inhibitory concentration (MIC) values of meropenem and colistin were detected by broth microdilution method in those isolates found resistant to carbapenems and sub-cultures of these isolates on glycerol broth were stored at -20°C. P. aeruginosa ATCC ® 27853 was used as a quality control strain (American Type Culture Collection [ATCC], Manassas, VA, USA).
Detection of bla genes responsible for carbapenem resistance in cR isolates by polymerase chain reaction (PcR)
Bacterial DNA was extracted from isolated colonies using QIAamp ® DNA Mini kit (Qiagen GmbH, Hilden, Germany). Amplification was done using Taq PCR Master Mix (Qiagen GmbH). Two multiplex PCRs were done; the first was for detection of genes encoding class A carbapenemase (bla KPC and bla GES ) and genes encoding class B metallo-beta-lactamases (MBL) (bla IMP and bla VIM ) in all isolates using primers and conditions described by Monteiro et al. 5 Klebsiella pneumoniae ATCC BAA-1705 was used as the positive control for bla KPC 20 except for the MIC values of tigecycline against A. baumannii where the standards specified for the Enterobacteriaceae family by the US Food and Drug Administration were used (susceptible, MIC ≤2 µg/mL, intermediate, MIC is >2 to <8 µg/mL, resistant, MIC ≥8 µg/mL). 21 antimicrobial combination testing 
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A. baumannii and P. aeruginosa: carbapenemases genes and combination testing by "Perpendicular E-test" method. Briefly, E-test strips of the two antimicrobials were placed on the agar at right angles intersecting at the respective MIC values previously determined for each antibiotic separately against the isolate. The agar plates were then incubated at 37°C for 18 hours. The MIC value of each antimicrobial in the combination was read. Interpretation of the ∑ FIC results was done as follows: ≤0.5, synergy; >0.5 to ≤1.0, additively; >1.0 to <4.0, indifference; and ≥4, antagonism. 23 When the individual MIC value of an isolate was more than the highest concentration on any of the E-test strips, the strips were placed intersecting at the highest concentration present on this E-test strip. The MIC value used to calculate the FIC index was then considered as one 2-fold dilution above the highest concentration on the E-test strip.
14 This was necessary for meropenem in most of the isolates where individual MIC values for meropenem were ≥32 µg/mL. This study was approved by the institutional review board (IRB) -Faculty of Medicine, Zagazig University. A written informed consent was obtained from each patient or the guardians of unconscious patients.
Results
Thirty out of 50 A. baumannii isolates (60%) and 22 out of 43 P. aeruginosa isolates (51%) tested were CR; they showed resistance to imipenem and meropenem by disc diffusion method as well as resistance to meropenem by broth microdilution (ie, MIC ≥8 µg/mL). These isolates were also resistant to the majority of the tested antibiotic classes expressing an MDR or XDR phenotype.
PCR results showed that all CR A. baumannii isolates harbored at least one of the genes under investigation. The most common resistance gene was bla in 90% of the isolates (27/30) followed by bla NDM in 66.7% of the isolates (20/30), then bla GES in 50% of the isolates (15/30), while the bla KPC , bla IMP , bla VIM , bla OXA-24 , bla OXA-58 and bla OXA-143 genes were not detected. On the other hand, all CR P. aeruginosa isolates harbored at least one of the tested genes except a single isolate in which none of the tested genes was detected. They showed high prevalence of class B carbapenemases where 18/22 (81.8%) harbored at least one of the tested MBL genes. Meanwhile bla GES was the only serine carbapenemase gene detected in (40.9%) of P. aeruginosa isolates ( Table 1) .
Meropenem MICs for CR A. baumannii isolates by broth dilution method ranged from 32 to 512 µg/mL ( Table 2) . By E-test, all meropenem MIC values were ≥32 µg/mL (ie, the maximum value on meropenem strip). All these isolates were colistin-sensitive by broth microdilution, where colistin MIC values ranged from 0.38 to 1.5 µg/mL. However, 15 isolates (50%) were tigecycline-resistant (MIC ≥8 µg/mL), 12 isolates (40%) were intermediate and three isolates (10%) were tigecycline-sensitive (MIC ≤2 µg/mL). MIC for tigecycline by E-test ranged from 2 to -16 µg/mL.
Meropenem MICs for CR P. aeruginosa isolates by broth dilution method ranged from 32 to 512 µg/mL (Table 2) . By E-test, all meropenem MIC values were ≥32 µg/mL. MICs for colistin ranged from 0.38 to 16 µg/mL. Twenty isolates (90.9%) were colistin-sensitive (MIC ≤2 µg/mL), and two isolates (9.1%) were resistant (MIC ≥4 µg/mL).
In the 30 CR A. baumannii isolates tested, both colistin/ meropenem and colistin/tigecycline combination showed additive effects against most of the isolates; 25 (83.3%) and 18 (60%), respectively (Figure 1 ), but synergism was only detected for colistin/tigecycline combination in six isolates (20%). Meanwhile, no antagonism was detected for either combinations (Table 3) . 
Figure 1 colistin/tigecycline combination test (Acinetobacter baumannii).
Notes: The MIc of colistin was 0.75 µg/ml when tested alone but was 0.25 µg/ ml when tested in combination. The MIc of tigecycline was 16 µg/ml when tested alone but was 3 µg/ml when tested in combination. This was an additive effect (isolate no. 12; Table s1 ). Abbreviation: MIc, minimum inhibitory concentration.
Figure 2 colistin/meropenem combination test (Pseudomonas aeruginosa).
Notes: The MIc of colistin was 0.75 µg/ml when tested alone but was 0.25 µg/ml when tested in combination. The MIc of meropenem was >32 µg/ml when tested alone but was 2 µg/ml when tested in combination. This was a synergistic effect (isolate no. 1; Table s2 ). Abbreviation: MIc, minimum inhibitory concentration. 
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Out of 22 CR P. aeruginosa isolates tested, the colistin/ meropenem combination showed synergistic effects against most 14 (63.6%) isolates ( Figure 2 ) and additive effect in eight (36.4%) isolates (Table 3) .
Discussion
This study depicts the increasingly reported threat of carbapenem resistance in the two frequently isolated Gram negative non-fermentative bacilli in Zagazig University Hospitals (ie, A. baumannii and P. aeruginosa), where 60% of A. baumannii and 43% of P. aeruginosa isolated over a 6-month period were CR. They all showed high level meropenem resistance with MIC values ranging from 32 to 512 µg/mL. In addition, they all exhibited an MDR profile being non-susceptible to at least one agent in at least three of the tested antimicrobial classes. This is attributed to the fact that mobile genetic elements carrying carbapenemase genes also carry genetic determinants of other antimicrobial resistance.
Screening our CR isolates for nine carbapenemase genes previously reported in our region yielded at least a single PCR product in 51/52 isolates which underscores the production of carbapenem-hydrolyzing enzymes as a common mechanism for high level carbapenem resistance displayed by our isolates. In a study in Saudi Arabia only 11 of 39 (18%) CR P. aeruginosa yielded a PCR product for carbapenemase genes. 24 Extended spectrum β-lactamases (ESBLs), porin mutations and/or presence of efflux pumps are other carbapenem resistance mechanisms that were implicated in carbapenem resistance in the absence of carbapenemase genes in tested isolates. 25 In CR A. baumannii isolates, bla OXA-23 was the most frequent carbapenemase gene and the only OXA-type carbapenemase detected in 27/30 (90%), followed by bla NDM in 20/30 (66.7%) then bla GES in 15/30 (50%). Kateete et al, in another African study, reported bla OXA-23 60% (9/15) as the most frequent OXA-type carbapenemase gene detected in CR A. baumannii followed by bla OXA-58 (2/15, 13%) and bla (1/15, 7%), while bla VIM was the only metallo-β-lactamase detected in 2/15 (13%) in such isolates. 26 The bla KPC gene, the metallo-β-lactamases (VIM, IMP) genes as well as other tested OXA-type genes were not detected in our CR A. baumannii isolates.
A. baumannii strains harboring bla have been reported to emerge around the world replacing bla OXA-58 that predominated for a long period among CR A. baumannii isolates and became the most prevalent carbapenemase gene circulating in different Mediterranean countries including Egypt. 27, 28 The higher carbapenemase activity of OXA-23
and/or horizontal gene transfer might provide a selective advantage for such isolates. 29 KPCs and GES-type class A carbapenemases have been described in A. baumannii. 30 Only GES-type carbapenemase was reported in Mediterranean countries. In addition, a Turkish study found that A. baumannii strains that belong to ST2, a part of the worldwide distributed clone II group, co-harbor both bla OXA-23 and bla . 31 This applies to the current study where bla GES , and not bla KPC (27.3%, 6/22) . In a study in Saudi Arabia, two MBL types, VIM and/or IMP, were detected in 12/34 CR P. aeruginosa isolates. 24 In Uganda, metallo-β-lactamase genes detected in CR P. aeruginosa were bla IMP1 (36%, 9/25), bla IMP2 (4%, 1/25), bla VIM1 (32%, 8/25), and bla NDM1 (4%, 1/25). 26 The KPC enzyme-encoding gene (bla KPC ), known to be prevalent among Enterobacteriaceae, was not detected in our isolates but was identified in Pseudomonas (16.9%) and Acinetobacter spp. (11.9%) from another Egyptian study. 35 In the past few years, antibiotic combination therapy has been employed as the standard for treating severe infections by CR GNB, particularly those with an XDR profile, justified by the possible additive or synergistic effect of adding drugs and by the broad spectrum activity that suppresses the emergence of resistant subpopulations if one antibiotic is used. 36 However, the irrational use of antibiotic combinations can worsen the existing antibiotic resistance problem. Thus, antibiotic combination should be rationally optimized based on preliminary in-vitro or animal studies followed by clinical trials on human subjects. Experts further recommend that combinations should be individualized based on the agent involved, its antibiotic susceptibility pattern, the type of infection and the patient's characteristics. 13 So far, most CR GNB are susceptible to colistin. In the present study all CR A. baumannii and 90.9% of CR P. aeruginosa isolates were colistin-sensitive and this nominates colistin to be a cornerstone drug in combination therapy. In CR A. baumannii, the colistin/meropenem combination showed additive effects in most (83.3%) of the isolates 
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Ramadan et al and indifferent effects in only 16.7%. This agrees with a recent Lebanese study where 'Perpendicular E-tests' showed additive effects of the colistin/meropenem combination in A. baumannii. Synergy, however, was not detected in either studies but a reduction of colistin MIC in combination means lower doses of colistin can be used in therapy, thus minimizing its toxic effects. 16 In CR P. aeruginosa, the colistin/meropenem combination showed better results where synergistic and additive effects were detected in 63.6% and 36.4% of the isolates, respectively. Daoud et al on testing this combination, found that six strains (54.5%) of A. baumannii and three (27.3%) strains of P. aeruginosa showed synergy while five (45.5%) strains of A. baumannii and seven (63.3%) strains of P. aeruginosa showed additive effect, while only one (9%) strain of P. aeruginosa showed antagonism. 37 On the other hand, the colistin/tigecycline combination against CR A. baumannii isolates showed synergistic, additive and indifferent effects in six (20%), 18 (60%) and six (20%), respectively. Karaoglan et al found that 96% and 64% of CR A. baumannii isolates were colistin-and tigecycline-sensitive, respectively. Meanwhile, the colistin/tigecycline combination revealed synergistic effects in 12% of such isolates. 38 Ni et al in a study on MDR A. baumannii strains, reported that the colistin/tigecycline combination had a synergistic effect in 24.3%. 39 In contrast, a recent Turkish study found colistin/ tigecycline combination synergistic in 2%, additive in 6%, indifferent in 88%, and antagonistic in 4% of A. baumannii isolates; all were tigecycline-and colistin-sensitive, concluding that the colistin/tigecycline combination is not an optimal treatment choice. 40 The synergistic or additive outcome of the colistin-based combination could be due to its ability to disrupt the bacterial outer membrane which facilitates the entry of the other agents into the bacterial cell. In addition, discrepant results of antibiotic combinations in different studies could be due to the different antibiotic selective pressure and genetic makeup of the isolates leading to their differential adaptation in different environments and consequently difference in their response to antimicrobial agents. 16 
Conclusion
High level carbapenem resistance detected in CR A. baumannii and CR P. aeruginosa in this study is attributed to the carriage of carbapenemase genes in different combinations. Colistin/tigecycline and colistin/meropenem combinations can be considered for treatment of severe infections by CR A. baumannii and P. aeruginosa, respectively, after adequate review of relevant pharmacodynamic and pharmacokinetic data. Moreover, the in vivo efficacy of these combinations needs to be proved by further clinical studies.
Limitations of the study
Primers used in this study amplify all alleles of the GES gene. So, a sequencing step would be helpful to differentiate between alleles of GES gene with ESBL and carbapenemase activities.
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